dsco Discovery Laboratories Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : dsco Discovery Laboratories

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: John McCarthy	12/7/2004 7:41:06 AM
	of 318

Discovery Labs Announces Encouraging Preliminary Data from ARDS Phase 2 Clinical Trial Tuesday December 7, 7:00 am ET Expands Trial to Strengthen Endpoint Signal Prior to Designing Potential Phase 3 Trial WARRINGTON, Pa., Dec. 7, 2004 (PRIMEZONE) -- Discovery Laboratories, Inc. (NasdaqNM:DSCO - News), announced encouraging preliminary data from its Surfaxin(r) Phase 2 clinical trial for the treatment of Acute Respiratory Distress Syndrome (ARDS) in adults. Discovery will hold a conference call today at 11:00 AM EST. The call in number is 800-665-0669. The ARDS Phase 2 trial is comprised of two parts; a dose-escalation/safety phase and an efficacy/safety phase. As of November 15, 2004, a total of 89 patients were enrolled in the trial and completed the 28-day study. The table below shows results from 78 evaluable patients. These evaluable patients received either one of two dosing regimens chosen for the efficacy/safety phase, or Standard of Care. DATA CHART ..... (I truly can't follow it but I assume it is at least mildly positive) biz.yahoo.com note:does anyone recall the size of the ARDS market. John McCarthy

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next